VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Aug 31, 2021

Keywords

ClinConnect Summary

The VICE-MPRINT trial is focused on understanding how genetic differences can affect how children and pregnant women respond to medications. This area of study, known as pharmacogenetics, is important for ensuring that treatments are safe and effective for everyone, particularly for groups like children and pregnant women who may be underrepresented in research. This trial aims to gather information about the knowledge and attitudes surrounding pharmacogenetic testing among diverse groups of children with chronic health conditions and pregnant women. Participants will watch an educational video about pharmacogenetic testing either when they receive their test results or later, and their understanding and feelings about the testing will be assessed before and after.

To be eligible for this study, pregnant women must be at least 18 years old, currently between 12 to 30 weeks of pregnancy, and receiving care at a specific clinic. They should also agree to share their medical information and receive the test results. For children, the trial includes those aged 0 to 16 with a chronic health condition, and parental consent is required. Participants will be asked to provide a DNA sample for testing, and everyone will complete surveys to share their thoughts and experiences. This research is crucial for improving how medications are prescribed and personalized for these specific groups.

Gender

ALL

Eligibility criteria

• • Maternal
• Inclusion Criteria:
• • Provide consent in English or Spanish
• • Primary care at VUMC
• • Adult women aged 18 and older
• • Currently pregnant 12 to 30 weeks gestational age
• • Completed or scheduled first prenatal visit at VUMC clinic
• • Intent to deliver at VUMC or affiliate
• • Agrees to receive findings from pharmacogenomic testing
• • Allow access their medical record
• Exclusion Criteria:
• • Stem cell or solid organ transplant
• • Recent transfusion within the previous 2 months
• • Inability to provide DNA sample for testing
• • Prior pharmacogenomic testing
• • Pregnant women undergoing in vitro fertilization or assisted reproductive technologies
• • Pediatric
• Inclusion Criteria:
• • Provide consent (parent/guardian) and/or assent (child) in English or Spanish
• • Primary care or subspecialty care at VUMC
• • Aged 0 to 16
• • Parent (0-16 years) and child (12-16 years) agree for both parent and child to receive findings from pharmacogenomic testing
• • Parent (0-16 years) and child (12-16 years) allow access their medical record
• • Have a chronic health condition.
• Exclusion:
• • Stem cell or solid organ transplant
• • Recent transfusion within the previous 2 months
• • Inability to provide DNA sample for testing
• • Prior pharmacogenomic testing